使用光导尖尖强烈脉冲光对沙拉齐安进行新的治疗
Yirui Zhu1,2,3, Hanhe Zhao1,2,3, Xiaodan Huang1,2,3
1Eye Center, School of Medicine, The Second Affiliated Hospital, Zhejiang University, 88 Jiefang Road, Hangzhou, 310009, Zhejiang, China.
Scientific reports
|July 31, 2023
概括
强烈脉冲光 (IPL) 与梅博米腺表达 (MGX) 有效地治疗沙拉,减少大小和复发. 这种非侵入性治疗也改善了梅博米腺的功能,为手术提供了一个有希望的替代方案.
科学领域:
- 眼科医生 眼科 眼科
- 医疗技术 医疗技术 医学技术
背景情况:
- 查拉齐昂是一种常见的眼炎症.
- 目前的切割和切割等治疗方法可能是侵入性的,并且有复发率.
- 梅博姆腺功能障碍通常与查拉齐安有关.
研究的目的:
- 为了评估光引导尖端强脉冲光 (IPL) 与梅博米腺表达 (MGX) 结合用于查拉齐安治疗的疗效.
- 为了比较IPL-MGX治疗与传统的切口和切口.
- 评估IPL-MGX对沙拉子体大小,复发和梅博米腺功能的影响.
主要方法:
- 一项前性研究涉及190只眼睛与chalazion.
- 95只眼睛接受了IPL-MGX治疗.
- 95只眼睛接受了切口和切割 (对照组).
- 收集的数据包括病变大小,高血压,回归,复发,非侵入性膜破裂时间 (NIBUT) 和梅布姆等级.
主要成果:
- 通过IPL-MGX治疗,可显著减少子的大小 (平均分辨率为70.5%),相当于切除手术.
- 与对照组相比,在IPL-MGX组中,沙拉复发率明显较低.
- 与基线和对照组相比,IPL-MGX显著改善了NIBUT和meibum等级.
结论:
- 带有MGX的光引导尖端IPL是一种有效的治疗Chalazion,减少大小和复发.
- 这种疗法还可以增强梅博姆腺的功能,解决潜在的原因.
- IPL-MGX为原发性或复发性沙拉西亚提供了一个可行的,潜在的第一线,非侵入性的治疗选择.
相关概念视频
01:28Angle Closure Glaucoma: Treatment
563
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
563
01:27Open Angle Glaucoma: Treatment
480
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
480